Bio-Rad (BIO) Q2 FY26 earnings call

Bio-Rad navigated a challenging Q2 FY26 with flat reported revenue and a slight currency-neutral decline, primarily impacted by ongoing softness in the academic research market and China. Despite these headwinds, the company saw sequential improvement, driven by a return to growth in Clinical Diagnostics and strong performance in Digital PCR instrument sales. Management is implementing a significant restructuring program to enhance agility and efficiency, aiming for substantial cost savings and operating margin expansion by 2027, while reaffirming full-year guidance.